IP Library › Granted Patent US 12,258,303
Granted Patent B2
US 12,258,303 · App. 18/532,133 · Granted Mar 25, 2025

Metal salts and uses thereof

Inventors: Stephen Wald (woodcliff Lake, NJ); Eduardo J. Martinez (Bryn Mawr, PA); Samuel Stratford (Cambridge, GB); Amanda Buist (Cambridge, GB); Joseph Benson (Edinburgh, GB); Jonathan Loughrey (Edinburgh, GB)
Assignee: Inspirna, Inc.
C07C229/34A61P35/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,303
App. No.
18/532,133
Granted
Mar 25, 2025
Kind
B2
Abstract

The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.

Claims (19)

1. A method of cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy] phenyl]acetic acid (Compound 1), wherein the zinc salt is a 2:1 (Compound 1:zinc) salt, and wherein the cancer is lung cancer or endometrial cancer.

2. The method of claim 1 , wherein the method comprises orally administering the zinc salt formulated as a pharmaceutical composition for oral administration comprising (i) the zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid (Compound 1), wherein the zinc salt is a 2:1 (Compound 1:zinc) salt, and (ii) a pharmaceutically acceptable excipient.

3. The method of claim 2 , wherein the pharmaceutical composition is in the form of an emulsion, an aqueous suspension, a dispersion, or a solution.

4. The method of claim 3 , wherein the pharmaceutical composition is in unit dosage form.

5. The method of claim 4 , wherein the pharmaceutical composition is a unit dosage form comprising a capsule or a tablet.

6. The method of claim 4 , wherein the pharmaceutical composition is a unit dosage form comprising a solution of the zinc salt.

7. The method of claim 1 , wherein the cancer is metastatic cancer.

8. The method of claim 7 , wherein the effective amount comprises an amount effective to delay onset of, reduce severity of, and/or reduce incidence of metastatic colonization of said cancer.

9. The method of claim 1 , wherein the subject has a cancer that has failed to respond to a previously administered immunotherapy.

10. The method of claim 1 , wherein the subject has a cancer resistant to an immunotherapy.

11. The method of claim 1 , wherein the cancer is lung cancer.

12. The method of claim 11 , wherein the cancer is non-small cell lung cancer.

13. The method of claim 1 , wherein the cancer is endometrial cancer.

14. The method of claim 1 , wherein the method further comprises administering an additional anticancer therapy to the subject.

15. The method of claim 14 , wherein the additional anticancer therapy is docetaxel.

16. The method of claim 15 , wherein the cancer is non-small cell lung cancer and the method comprises administering (1) a zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy] phenyl]acetic acid (Compound 1), wherein the zinc salt is a 2:1 (Compound 1:zinc) salt, and (2) docetaxel to the subject.

17. The method of claim 15 , wherein the cancer is non-small cell lung cancer and the method comprises administering (1) a zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy] phenyl]acetic acid (Compound 1), wherein the zinc salt is a 2:1 (Compound 1:zinc) salt, (2) docetaxel, and (3) ipilimumab to the subject.

18. The method of claim 14 , wherein the additional anticancer therapy is ipilimumab.

19. The method of claim 18 , wherein the cancer is endometrial cancer and the method comprises administering (1) a zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy] phenyl]acetic acid (Compound 1), and (2) ipilimumab to the subject.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: BENSON, JOSEPH; LOUGHREY, JONATHAN
To: SOLID FORM SOLUTIONS LIMITED
Reel/Frame 066474/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: WALD, STEPHEN; MARTINEZ, EDUARDO J.
To: RGENIX, INC.
Reel/Frame 066474/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: STRATFORD, SAMUEL; BUIST, AMANDA
To: JOHNSON MATTHEY PLC
Reel/Frame 066474/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: JOHNSON MATTHEY PLC
To: RGENIX, INC.
Reel/Frame 066474/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: SOLID FORM SOLUTIONS LIMITED
To: RGENIX, INC.
Reel/Frame 066475/0024 →
CHANGE OF NAME Recorded Feb 16, 2024
From: RGENIX, INC.
To: INSPIRNA, INC.
Reel/Frame 066615/0232 →
Continuity (5)
Continuation 17821699 · Aug 23, 2022
Continuation 17407394 · Aug 20, 2021
Continuation 17119527 · Dec 11, 2020
Provisional Application 62947968 · Dec 13, 2019
Related Publication 20240174595A1 · May 30, 2024
References Cited (400)
US 4683202A · Mullis · 1987 [cited by applicant]
US 5215882A · Bahl et al. · 1993 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5324731A · Kaddurah-Daouk et al. · 1994 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5639641A · Pedersen et al. · 1997 [cited by applicant]
US 5676978A · Teicher et al. · 1997 [cited by applicant]
US 5707807A · Kato · 1998 [cited by applicant]
US 5807522A · Brown et al. · 1998 [cited by applicant]
US 5837832A · Chee et al. · 1998 [cited by applicant]
US 5843974A · Swift · 1998 [cited by applicant]
US 5945289A · Lehrer · 1999 [cited by applicant]
US 5958342A · Gamble et al. · 1999 [cited by applicant]
US 5994076A · Chenchik et al. · 1999 [cited by applicant]
US 6004755A · Wang · 1999 [cited by applicant]
US 6040138A · Lockhart et al. · 2000 [cited by applicant]
US 6048695A · Bradley et al. · 2000 [cited by applicant]
US 6060240A · Kamb et al. · 2000 [cited by applicant]
US 6087112A · Dale · 2000 [cited by applicant]
US 6090556A · Kato · 2000 [cited by applicant]
US 6316503B1 · Li et al. · 2001 [cited by applicant]
US 6652860B1 · Singh et al. · 2003 [cited by applicant]
US 6716622B2 · Curiel et al. · 2004 [cited by applicant]
US 6906069B1 · Li et al. · 2005 [cited by applicant]
US 7135575B2 · Munson et al. · 2006 [cited by applicant]
US 7183295B2 · Yamazaki et al. · 2007 [cited by applicant]
US 7247748B2 · Thompson et al. · 2007 [cited by applicant]
US 7365085B2 · Bhat et al. · 2008 [cited by applicant]
US 7476519B2 · Monforte · 2009 [cited by applicant]
US 7560586B2 · Thompson et al. · 2009 [cited by applicant]
US 7576215B2 · Collini et al. · 2009 [cited by applicant]
US 7741317B2 · Chao et al. · 2010 [cited by applicant]
US 7790745B2 · Yang et al. · 2010 [cited by applicant]
US 7799782B2 · Munson et al. · 2010 [cited by applicant]
US 7897750B2 · Monforte · 2011 [cited by applicant]
US 7998995B2 · Boren et al. · 2011 [cited by applicant]
US 8039493B2 · Dehmlow et al. · 2011 [cited by applicant]
US 8236753B2 · Blacklow et al. · 2012 [cited by applicant]
US 8257750B2 · Ranganathan · 2012 [cited by applicant]
US 8324367B2 · Kaemmerer et al. · 2012 [cited by applicant]
US 8357679B2 · Cooke et al. · 2013 [cited by applicant]
US 8993628B2 · Forman et al. · 2015 [cited by applicant]
US 9399028B2 · Tavazoie et al. · 2016 [cited by applicant]
US 9421218B2 · Hernando et al. · 2016 [cited by applicant]
US 9526710B2 · Tavazoie et al. · 2016 [cited by applicant]
US 9707195B2 · Tavazoie et al. · 2017 [cited by applicant]
US 9827217B2 · Martinez et al. · 2017 [cited by applicant]
US 9884813B1 · Martinez et al. · 2018 [cited by applicant]
US 9962348B2 · Tavazoie et al. · 2018 [cited by applicant]
US 10543183B2 · Tavazoie et al. · 2020 [cited by applicant]
US 10669296B2 · Martinez et al. · 2020 [cited by applicant]
US 10869926B2 · Zhou et al. · 2020 [cited by applicant]
US 10945978B2 · Tavazoie et al. · 2021 [cited by applicant]
US 11174220B2 · Wald et al. · 2021 [cited by applicant]
US 11214536B2 · Chitre et al. · 2022 [cited by applicant]
US 11459292B2 · Wald et al. · 2022 [cited by applicant]
US 11648220B2 · Tavazoie et al. · 2023 [cited by applicant]
US 11865094B2 · Tavazoie et al. · 2024 [cited by applicant]
US 11878956B2 · Wald et al. · 2024 [cited by applicant]
US 20020022018A1 · Curiel et al. · 2002 [cited by applicant]
US 20020107233A1 · Liao et al. · 2002 [cited by applicant]
US 20030022375A1 · Itoh et al. · 2003 [cited by applicant]
US 20030027335A1 · Ruley et al. · 2003 [cited by applicant]
US 20030027845A1 · Marfat et al. · 2003 [cited by applicant]
US 20030125357A1 · Adams et al. · 2003 [cited by applicant]
US 20030153541A1 · Dudley et al. · 2003 [cited by applicant]
US 20040072868A1 · Collins et al. · 2004 [cited by applicant]
US 20040087632A1 · Van Camp et al. · 2004 [cited by applicant]
US 20040216178A1 · Jones et al. · 2004 [cited by applicant]
US 20050080111A1 · Bayne et al. · 2005 [cited by applicant]
US 20050107444A1 · Thompsom et al. · 2005 [cited by applicant]
US 20050113419A1 · Huang et al. · 2005 [cited by applicant]
US 20050113580A1 · Thompson et al. · 2005 [cited by applicant]
US 20050130919A1 · Xu et al. · 2005 [cited by applicant]
US 20050131014A1 · Collini et al. · 2005 [cited by applicant]
US 20050215577A1 · Dehmlow et al. · 2005 [cited by applicant]
US 20050245515A1 · Dehmlow et al. · 2005 [cited by applicant]
US 20050261319A1 · Deuschle et al. · 2005 [cited by applicant]
US 20050282908A1 · Collins et al. · 2005 [cited by applicant]
US 20050289659A1 · Jacks et al. · 2005 [cited by applicant]
US 20060030612A1 · Steffan et al. · 2006 [cited by applicant]
US 20060074115A1 · Dehmlow et al. · 2006 [cited by applicant]
US 20060135601A1 · Dehmlow et al. · 2006 [cited by applicant]
US 20060160079A1 · Lane · 2006 [cited by applicant]
US 20060178398A1 · Adams et al. · 2006 [cited by applicant]
US 20070093524A1 · Nambi et al. · 2007 [cited by applicant]
US 20070161553A1 · Mathieu et al. · 2007 [cited by applicant]
US 20080085879A1 · Xie et al. · 2008 [cited by applicant]
US 20090004297A1 · Ranganathan · 2009 [cited by applicant]
US 20090030082A1 · Forman · 2009 [cited by applicant]
US 20090099066A1 · Moulton et al. · 2009 [cited by applicant]
US 20090175791A1 · Kavile et al. · 2009 [cited by applicant]
US 20090247587A1 · Okuda et al. · 2009 [cited by applicant]
US 20090286780A1 · Okuda et al. · 2009 [cited by applicant]
US 20100048944A1 · Parhami · 2010 [cited by applicant]
US 20100056481A1 · Glausch et al. · 2010 [cited by applicant]
US 20100069367A1 · Boren et al. · 2010 [cited by applicant]
US 20100249096A1 · Aay et al. · 2010 [cited by applicant]
US 20100273816A1 · Bernotas et al. · 2010 [cited by applicant]
US 20100279918A1 · Langel et al. · 2010 [cited by applicant]
US 20100284990A1 · Kaemmerer et al. · 2010 [cited by applicant]
US 20100298410A1 · Obad et al. · 2010 [cited by applicant]
US 20110028384A1 · Blacklow et al. · 2011 [cited by applicant]
US 20110112135A1 · Singhaus, Jr. et al. · 2011 [cited by applicant]
US 20110166079A1 · Vitek et al. · 2011 [cited by applicant]
US 20110237791A1 · Kawaguchi et al. · 2011 [cited by applicant]
US 20120156216A1 · Oh · 2012 [cited by applicant]
US 20120156263A1 · Choy et al. · 2012 [cited by applicant]
US 20120231457A1 · Tezapsidis et al. · 2012 [cited by applicant]
US 20130004481A1 · Solca et al. · 2013 [cited by applicant]
US 20130071403A1 · Rolland et al. · 2013 [cited by applicant]
US 20140186295A1 · Kupper et al. · 2014 [cited by applicant]
US 20150023955A1 · Tavazoie et al. · 2015 [cited by applicant]
US 20150033693A1 · Ito et al. · 2015 [cited by applicant]
US 20150045399A1 · Mohan · 2015 [cited by applicant]
US 20150051214A1 · Dong et al. · 2015 [cited by applicant]
US 20150065515A1 · Dong et al. · 2015 [cited by applicant]
US 20150073053A1 · Tavazoie et al. · 2015 [cited by applicant]
US 20150080406A1 · Leftheris et al. · 2015 [cited by applicant]
US 20150150941A1 · Weinberg et al. · 2015 [cited by applicant]
US 20150152094A1 · Mohan · 2015 [cited by applicant]
US 20150225366A1 · Li · 2015 [cited by applicant]
US 20150246924A1 · Dong et al. · 2015 [cited by applicant]
US 20150299136A1 · Busch et al. · 2015 [cited by applicant]
US 20160271149A1 · Einhorn · 2016 [cited by applicant]
US 20170066791A1 · Martinez et al. · 2017 [cited by applicant]
US 20170119807A1 · Lee et al. · 2017 [cited by applicant]
US 20180072810A1 · Afar et al. · 2018 [cited by applicant]
US 20190029984A1 · Tavazoie et al. · 2019 [cited by applicant]
US 20190125745A1 · Martinez et al. · 2019 [cited by applicant]
US 20210220306A1 · Tavazoie et al. · 2021 [cited by applicant]
US 20220127680A1 · Tavazoie et al. · 2022 [cited by applicant]
AU 1552599A · 1999 [cited by applicant]
AU 2003222083A1 · 2003 [cited by applicant]
AU 2003226094A1 · 2003 [cited by applicant]
AU 2005272043B2 · 2006 [cited by applicant]
AU 2006227435A1 · 2006 [cited by applicant]
CA 2592367C · 2011 [cited by applicant]
CN 88102538A · 1988 [cited by applicant]
CN 101952293A · 2011 [cited by applicant]
CN 103054844B · 2014 [cited by applicant]
CN 104780976A · 2015 [cited by applicant]
CN 108738323A · 2018 [cited by applicant]
CN 109251974A · 2019 [cited by applicant]
DE 2951400A1 · 1981 [cited by applicant]
EP 0015505B1 · 1984 [cited by applicant]
EP 0288962A2 · 1988 [cited by applicant]
EP 519596A1 · 1992 [cited by applicant]
EP 0592106A1 · 1994 [cited by applicant]
EP 0747053A2 · 1996 [cited by applicant]
EP 0735144B1 · 2002 [cited by applicant]
EP 2235019A1 · 2010 [cited by applicant]
EP 2474617A1 · 2012 [cited by applicant]
EP 2188266B1 · 2012 [cited by applicant]
EP 2584045A1 · 2013 [cited by applicant]
ES 2233700T3 · 2005 [cited by applicant]
ES 2525217T3 · 2014 [cited by applicant]
ES 2694726T3 · 2018 [cited by applicant]
FR 2865736B1 · 2006 [cited by applicant]
GB 946902A · 1964 [cited by applicant]
JP H11507371A · 1999 [cited by applicant]
JP 200333179A · 2003 [cited by applicant]
JP 2006232703A · 2006 [cited by applicant]
JP 2008509948A · 2008 [cited by applicant]
JP 2008526841A · 2008 [cited by applicant]
JP 2008179562A · 2008 [cited by applicant]
JP 2011525616A · 2011 [cited by applicant]
JP 2012503984A · 2012 [cited by applicant]
JP 2012528180A · 2012 [cited by applicant]
JP 5399262B2 · 2014 [cited by applicant]
JP 5511079B2 · 2014 [cited by applicant]
JP 2015532642A · 2015 [cited by applicant]
JP 5851400B2 · 2016 [cited by applicant]
JP 2019507115A · 2019 [cited by applicant]
KR 1020070116060A · 2007 [cited by applicant]
KR 1020100102110A · 2010 [cited by applicant]
MX 2010012579A · 2010 [cited by applicant]
RU 2383524C2 · 2010 [cited by applicant]
TW 200606157A · 2006 [cited by applicant]
TW 200825054A · 2008 [cited by applicant]
TW 200922582A · 2009 [cited by applicant]
TW 201930256A · 2019 [cited by applicant]
WO WO9516791A1 · 1995 [cited by applicant]
WO WO9639135A1 · 1996 [cited by applicant]
WO WO0066611A1 · 2000 [cited by applicant]
WO WO0166534A2 · 2001 [cited by applicant]
WO WO0213594A1 · 2002 [cited by applicant]
WO WO0224632A2 · 2002 [cited by applicant]
WO WO02090375A2 · 2002 [cited by applicant]
WO WO03031408A2 · 2003 [cited by applicant]
WO WO03043998A1 · 2003 [cited by applicant]
WO WO03045382A1 · 2003 [cited by applicant]
WO WO03059874A2 · 2003 [cited by applicant]
WO WO03059884A1 · 2003 [cited by applicant]
WO WO03060078A2 · 2003 [cited by applicant]
WO WO03082198A2 · 2003 [cited by applicant]
WO WO03082205A2 · 2003 [cited by applicant]
WO WO03082802A1 · 2003 [cited by applicant]
WO WO03090732A1 · 2003 [cited by applicant]
WO WO03090746A1 · 2003 [cited by applicant]
WO WO03090869A1 · 2003 [cited by applicant]
WO WO03099769A1 · 2003 [cited by applicant]
WO WO03099775A1 · 2003 [cited by applicant]
WO WO03106435A1 · 2003 [cited by applicant]
WO WO2004009091A1 · 2004 [cited by applicant]
WO WO2004011448A1 · 2004 [cited by applicant]
WO WO2004026816A1 · 2004 [cited by applicant]
WO WO2004043939A1 · 2004 [cited by applicant]
WO WO2004058717A1 · 2004 [cited by applicant]
WO WO2004072041A1 · 2004 [cited by applicant]
WO WO2004072042A2 · 2004 [cited by applicant]
WO WO2004072046A2 · 2004 [cited by applicant]
WO WO2004078939A2 · 2004 [cited by applicant]
WO WO2005005416A1 · 2005 [cited by applicant]
WO WO2005005417A1 · 2005 [cited by applicant]
WO WO2005016277A2 · 2005 [cited by applicant]
WO WO2005023782A1 · 2005 [cited by applicant]
WO WO2005039643A2 · 2005 [cited by applicant]
WO WO2005058834A2 · 2005 [cited by applicant]
WO WO2005077122A2 · 2005 [cited by applicant]
WO WO2005077124A2 · 2005 [cited by applicant]
WO WO2005112620A2 · 2005 [cited by applicant]
WO WO2005113499A1 · 2005 [cited by applicant]
WO WO2006000323A1 · 2006 [cited by applicant]
WO WO2006003923A1 · 2006 [cited by applicant]
WO WO2006004030A1 · 2006 [cited by applicant]
WO WO2006017055A2 · 2006 [cited by applicant]
WO WO2006018182A1 · 2006 [cited by applicant]
WO WO2006046593A1 · 2006 [cited by applicant]
WO WO2006073363A1 · 2006 [cited by applicant]
WO WO2006073364A1 · 2006 [cited by applicant]
WO WO2006073365A1 · 2006 [cited by applicant]
WO WO2006073366A1 · 2006 [cited by applicant]
WO WO2006073367A1 · 2006 [cited by applicant]
WO WO2006094034A1 · 2006 [cited by applicant]
WO WO2006102067A1 · 2006 [cited by applicant]
WO WO2006109633A1 · 2006 [cited by applicant]
WO WO2007002563A1 · 2007 [cited by applicant]
WO WO2007022563A1 · 2007 [cited by applicant]
WO WO2007047991A1 · 2007 [cited by applicant]
WO WO2007050425A2 · 2007 [cited by applicant]
WO WO2007081335A1 · 2007 [cited by applicant]
WO WO2007092065A2 · 2007 [cited by applicant]
WO WO2007110755A1 · 2007 [cited by applicant]
WO WO2008011071A2 · 2008 [cited by applicant]
WO WO2008027988A2 · 2008 [cited by applicant]
WO WO2008049047A2 · 2008 [cited by applicant]
WO WO2008065754A1 · 2008 [cited by applicant]
WO WO2009020683A2 · 2009 [cited by applicant]
WO WO2009021868A2 · 2009 [cited by applicant]
WO WO2009024550A1 · 2009 [cited by applicant]
WO WO2009040289A2 · 2009 [cited by applicant]
WO WO2009043353A2 · 2009 [cited by applicant]
WO WO2009074467A1 · 2009 [cited by applicant]
WO WO2009086123A1 · 2009 [cited by applicant]
WO WO2009086129A1 · 2009 [cited by applicant]
WO WO2009086130A1 · 2009 [cited by applicant]
WO WO2009086138A1 · 2009 [cited by applicant]
WO WO2009133692A1 · 2009 [cited by applicant]
WO WO2009138438A1 · 2009 [cited by applicant]
WO WO2009144961A1 · 2009 [cited by applicant]
WO WO2009148915A2 · 2009 [cited by applicant]
WO WO2009150109A1 · 2009 [cited by applicant]
WO WO2010023317A1 · 2010 [cited by applicant]
WO WO2010025169A2 · 2010 [cited by applicant]
WO WO2010025179A1 · 2010 [cited by applicant]
WO WO2010036613A1 · 2010 [cited by applicant]
WO WO2010036959A2 · 2010 [cited by applicant]
WO WO2010059627A1 · 2010 [cited by applicant]
WO WO2010125811A1 · 2010 [cited by applicant]
WO WO2010138598A2 · 2010 [cited by applicant]
WO WO2011014661A2 · 2011 [cited by applicant]
WO WO2011051282A1 · 2011 [cited by applicant]
WO WO2011055391A1 · 2011 [cited by applicant]
WO WO2011103175A2 · 2011 [cited by applicant]
WO WO2011115892A1 · 2011 [cited by applicant]
WO WO2011130426A2 · 2011 [cited by applicant]
WO WO2011158667A1 · 2011 [cited by applicant]
WO WO2012004748A1 · 2012 [cited by applicant]
WO WO2012095505A1 · 2012 [cited by applicant]
WO WO2012096573A1 · 2012 [cited by applicant]
WO WO2012135082A1 · 2012 [cited by applicant]
WO WO2013039764A1 · 2013 [cited by applicant]
WO WO2013043569A1 · 2013 [cited by applicant]
WO WO2013057148A1 · 2013 [cited by applicant]
WO WO2013076257A1 · 2013 [cited by applicant]
WO WO2013130892A1 · 2013 [cited by applicant]
WO WO2013138565A1 · 2013 [cited by applicant]
WO WO2013138568A1 · 2013 [cited by applicant]
WO WO2014028461A2 · 2014 [cited by applicant]
WO WO2014144037A1 · 2014 [cited by applicant]
WO WO2015065505A1 · 2015 [cited by applicant]
WO WO2015106164A1 · 2015 [cited by applicant]
WO WO2016100619A2 · 2016 [cited by applicant]
WO WO2017123568A2 · 2017 [cited by applicant]
WO WO2017135412A1 · 2017 [cited by applicant]
WO WO2017161188A1 · 2017 [cited by applicant]
WO WO2017181163A2 · 2017 [cited by applicant]
WO WO2018161054A1 · 2018 [cited by applicant]
WO WO2019104062A1 · 2019 [cited by applicant]
WO WO2020176846A2 · 2020 [cited by applicant]
WO WO2020205644A1 · 2020 [cited by applicant]
WO WO2021119397A1 · 2021 [cited by applicant]
NCT02922764, clinical trial.gov, Nov. 2016 (Year: 2016). [cited by examiner]
“Definition of Cancer,” MedicineNet.com, <http://www.medterms.com/script/main/art.asp?articlekey=2580&pf=3&page=1>, retrieved on Mar. 8, 2011 (2 pages). [cited by applicant]
Adeyeye et al., “Diclofenac sodium,” Analytical Profiles of Drug Substances. 19:123-44 (1990) (23 pages). [cited by applicant]
Antonia et al., “Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results,” American Society of Clinical Oncology Annual Meeting 1. 32(15 suppl) Abstract 8023 (May 20, 2014… [cited by applicant]
Bartel, “MicroRNAs: Target Recognition and Regulatory Functions,” Cell. 136(2): 215-233 (2009). [cited by applicant]
Bastin et al., “Salt selection and optimisation procedures for pharmaceutical new chemical entities,” Org Process Res Dev 4(5):427-35 (2000). [cited by applicant]
Benn et al., “Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study,” J Natl Cancer Inst. 103(6):508-19 (Mar. 16, 2011). [cited by applicant]
Berge et al., “Pharmaceutical salts,” J Pharm Sci. 66(1):1-19 (1977). [cited by applicant]
Bergenfelz et al., “Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients,” PLOS One. 10(5):e0127028 (2015) (23 pages). [cited by applicant]
Bird et al., “Single-chain antigen-binding proteins,” Science. 242(4877):423-6 (1988) (5 pages). [cited by applicant]
Bobin-Dubigeon et al., “Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity,” Anticancer Res. 37(10):5495-5498 (2017). [cited by applicant]
Bordwell et al., “Synthesis of aryl methyl sulfoxides and determination of the conjugative effect of the methylsulfinyl group,” J Am Chem Soc. 79(3): 717-22 (1957). [cited by applicant]
Brunton et al., “Goodman and Gilman's The Pharmacological Basis of Therapeutics,” McGraw Hill Companies (2011). [cited by applicant]
Bustin, “Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays,” Journal of Molecular Endocrinology. 25(2): 169-193 (2000). [cited by applicant]
Caira, “Crystalline polymorphism of organic compounds,” [cited by applicant]
Calin et al., “MicroRNA signatures in human cancers,” Nat Rev Cancer. 6:857-866 (2007). [cited by applicant]
CAPLUS AN 1981:121135 for Ostermayer et al., “3-Amino-1, 2-propane diol derivatives and pharmaceutical compositions containing them,” (1981) (2 pages). [cited by applicant]
CAPLUS AN 1981:586827 for Mohr, R., “N, N′ - Diarylethylendiamines or N, N′, N″-triaryldiethylenetriamines,” (1981) (1 page). [cited by applicant]
CAPLUS AN 1983:178855 for Fujikura et al., “Studies on benzenesulfonamide derivatives with α- and β-adrenergic antagonistic and antihypertensive activities,” Chemical & Pharmaceutical Bulletin 30(11):4092-101 (1982). [cited by applicant]
CAPLUS AN 2002:240713 for Collins et al., “Preparation of substituted phenylacetamides and benzamides as agonists for Liver X receptors (LXR),” (2002) (2 pages). [cited by applicant]
CAPLUS AN 2003:796421 for Cairns et al., “Methods of treatment with LXR modulators,” (2003). [cited by applicant]
CAPLUS AN 2003:796645 for Thompson et al., “Preparation of (hetero)arylalkanoic acids and esters as LXR agonists,” (2003) (2 pages). [cited by applicant]
CAPLUS, AN 2005:238962, for Yamazaki et al., “Preparation of azole compounds as PPAR-alpha agonists,” (2005) (4 pages). [cited by applicant]
CAPLUS, AN 2006:910678, for Yamaguchi et al., “Preparation of phenoxyacetic acid compounds containing furan moiety as peroxisome proliferator activation receptor (PPAR) alpha/gamma agonists,” (2006) (2 pages). [cited by applicant]
Carell et al., “A Solution-Phase Screening Procedure for the Isolation of Active Compounds from a Library of Molecules,” Angewandte Chemie International Edition in English. 33(20): 2061-2064 (1994). [cited by applicant]
Chang et al., “Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients,” Clin Chim Acta. 401(1-2):144-7 (Mar. 2009). [cited by applicant]
Chinese Office Action issued Aug. 30, 2021 in related Chinese Application No. 2018115020665 (20 pages). [cited by applicant]
Cho et al., “An unnatural biopolymer,” Science. 261(5126):1303-1305 (1993). [cited by applicant]
Chuu et al., “Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines,” Anticancer Res. 30(9):3643-8 (2010). [cited by applicant]
Chuu et al., “Modulation of liver X receptor signaling as novel therapy for prostate cancer,” J Biomed Sci. 14(5):543-553 (2007). [cited by applicant]
Communication pursuant to Article 94(3) EPC for European Application No. 13829165.3, dated Jan. 15, 2018 (5 pages). [cited by applicant]
Communication pursuant to Article 94(3) EPC for European Application No. 15734952.3, dated Jul. 18, 2019 (6 pages). [cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 15734952.3, dated Aug. 29, 2018 (6 pages). [cited by applicant]
Cristiano et al., “Molecular conjugates: a targeted gene delivery vector for molecular medicine,” J Mol Med. 73:479-486 (1995). [cited by applicant]
Cull et al., “Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor,” Proc Natl Acad Sci. 89(5):1865-1869. (1992). [cited by applicant]
Cwirla et al., “Peptides on phage: A vast library of peptides for identifying ligands,” Proc Nati Acad Sci. 87:6378-6382 (1990). [cited by applicant]
Devlin et al., “Random Peptide Libraries: a Source of Specific Protein Binding Molecules,” Science. 249(4967):404-406 (1990). [cited by applicant]
DeWitt et al., “‘Diversomers”’: an approach to nonpeptide, nonoligomeric chemical diversity, Proc Natl Acad Sci. 90(15):6909-6913 (1993). [cited by applicant]
Domingues et al., “Immunotherapy and lung cancer: current developments and novel targeted therapies,” Immunotherapy. 6(11):1221-35 (Dec. 12, 2014) (Abstract only). [cited by applicant]
Draghiciu et al., “Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy,” Oncoimmunology. 4(1):e954829 (Feb. 3, 2015) (10 pages). [cited by applicant]
Erb et al., “Recursive deconvolution of combinatorial chemical libraries,” Proc Natl Acad Sci. 91(24):11422-11426 (1994). [cited by applicant]
Examination Report No. 1 for Australian Patent Application No. 2013302861, dated Sep. 8, 2017 (6 pages). [cited by applicant]
Extended European Search Report for European Application No. 13829165.3, dated Jun. 8, 2016 (12 pages). [cited by applicant]
Extended European Search Report for European Application No. 18880192.2, dated Jul. 23, 2021 (9 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 20897654.8, dated Jun. 7, 2023 (5 Pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 15734952.3, dated Jul. 6, 2017 (8 pages). [cited by applicant]
Fabian et al., “Regulation of mRNA Translation and Stability by microRNAs,” Annu Rev Biochem. 79:351-379 (2010) (32 pages). [cited by applicant]
Felici et al., “Selection of Antibody Ligands from a Large Library of Oligopeptides Expressed on a Multivalent Exposition Vector,” J Mol Biol. 222:301-310 (1991). [cited by applicant]
Filipowicz et al., “Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?,” Nat Rev Genet. 9:102-114 (2008). [cited by applicant]
First Examination Report for Australian Application No. 2015204572, dated Jul. 15, 2019 (7 pages). [cited by applicant]
First Office Action and Search Report for Chinese Application No. 2013800534784, dated Aug. 1, 2017 (19 pages). [cited by applicant]
Fodor et al., “Multiplexed biochemical assays with biological chips,” Nature. 364:555-556 (1993). [cited by applicant]
Fowler et al., “Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production,” J… [cited by applicant]
Fymat, “Harnessing the immune system to treat cancers and neurodegenerative diseases,” Clinical Research in Neurology 1(1):1-14 (Apr. 4, 2018). [cited by applicant]
Gallop et al., “Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries,” J Med Chem 37(9):1233-51 (1994). [cited by applicant]
Garbe et al., “Melanoma epidemiology and trends,” Clinics in Dermatology. 27(1): 3-9 (2009). [cited by applicant]
Garbe et al., “Systematic review of medical treatment in melanoma: current status and future prospects,” Oncologist. 16(1):5-24 (2011). [cited by applicant]
Garzon et al., “Targeting microRNAs in cancer: rationale, strategies and challenges,” available in PMC Jan. 28, 2014, published in final edited form as: Nat Rev Drug Discov. 9(10):775-789 (Oct. 2010) (26 pages). [cited by applicant]
Gielen et al., “Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppresor Cell Subpopulations in the Blood of Patients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppresor Cells in Gl… [cited by applicant]
Ginzinger, “Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream,” Exp Hematol. 30(6): 503-512 (2002). [cited by applicant]
Groot et al., “Synthetic LXR agonists increase LDL in CETP species,” J Lipid Res. 46(10):2182-91 (2005). [cited by applicant]
Gros et al., “Myeloid Cells Obtained from the Blood but Not from the Tumor can Suppress T-cell Proliferation in Patients with Melanoma,” Clin Cancer Res. 18(19):5212-5223 (2012). [cited by applicant]
Guo et al., “Mammalian microRNAs predominantly act to decrease target mRNA levels,” Nature. 466:835-840 (2010). [cited by applicant]
Guo et al., “Research Progress in Apolipoprotein E in Thrombosis-related Diseases and Malignant Tumors,” Chinese General Practice. 16(2B):590-2 (2013). English abstract included. [cited by applicant]
Gupta et al., “Cancer Metastasis: Building a Framework,” Cell. 127(4):679-695 (2006). [cited by applicant]
Gupta et al., “Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis,” Nature. 464:1071-1076 (2010) (8 pages). [cited by applicant]
Guttman et al., “Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals,” Nature. 458:223-227 (2009). [cited by applicant]
Haas, “Melanoma: three ways around BRAF inhibition,” SciBX. 3(47):(2010) (3 pages). [cited by applicant]
Hanahan et al., “Hallmarks of Cancer: The Next Generation,” Cell. 144(5):646-674 (2011). [cited by applicant]
Haqq et al., “The gene expression signatures of melanoma progression,” Proc Natl Acad Sci USA. 102(17):6092-6097 (2005). [cited by applicant]
Hatters et al., “Apolipoprotein E structure: insights into function,” Trends in Biochemical Sciences. 31(8):445-454 (2006). [cited by applicant]
Hatziapostolou et al., “An HNF4alpha-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis,” Cell. 147(6):1233-1247 (2011). [cited by applicant]
Hauser et al., “Apolipoprotein E: From lipid transport to neurobiology,” Progress in Lipid Research. 50(1):62-74 (2001). [cited by applicant]
Huang et al., “The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis,” Nat Cell Biol. 10(2):202-210 (2008) (24 pages). [cited by applicant]
Huarte et al., “A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response,” Cell. 142(3):409-419 (2010). [cited by applicant]
Hurst et al., “Metastamir: The Field of Metastasis-Regulatory microRNA Is Spreading,” Cancer Res. 69(19):7495-7498 (2009). [cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Hynes et al., “Metastatic Potential: generic predisposition of the primary tumor or rare, metastatic variants—or both?” Cell. 113(7):821-823 (2003). [cited by applicant]
Iclozan et al., “Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer,” available in PMC May 1, 2014, published in fina… [cited by applicant]
Inglis et al., “Synthesis and evaluation of 3-(Dihydroxyboryl)benzoic acids as D,D- Carboxypeptidase R39 inhibitors,” J Med Chem. 52(19):6097-106 (2009). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US15/66289, dated Jun. 29, 2017 (7 pages). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2015/010909, mailed Jul. 21, 2016 (7 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US15/66289, mailed Feb. 25, 2016 (14 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US17/12906, mailed Jun. 30, 2017 (14 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US18/62063, mailed Feb. 4, 2019 (20 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/50075, mailed Feb. 10, 2021 (16 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/64456, mailed Mar. 3, 2021 (13 pages). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2015/010909, mailed Jun. 11, 2015 (14 pages). [cited by applicant]
International Search Report for International Application No. PCT/US13/54690, mailed Feb. 21, 2014 (10 pages). [cited by applicant]
International Search Report for International Application No. PCT/US20/20349, mailed Oct. 29, 2020 (8 pages). [cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2015/010909, mailed Mar. 11, 2015 (3 pages). [cited by applicant]
Jemal et al., “Cancer Statistics, 2008,” CA Cancer J Clin. 58(2):71-96 (2008). [cited by applicant]
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials,” Br J Cancer. 84(10):1424-31 (2001). [cited by applicant]
Ju et al., “Liver X receptors as potential targets for cancer therapeutics,” Oncol Lett. 14(6):7676-80 (2017). [cited by applicant]
Kang et al., “A multigenic program mediating breast cancer metastasis to bone,” Cancer Cell. 3(6):537-549 (2003). [cited by applicant]